Adherence to Ombitasvir/Paritaprevir/r, Dasabuvir, and Ribavirin is >98% in the SAPPHIRE-I and SAPPHIRE-II Trials

Press/Media: Press / Media

PeriodMay 19 2015

Media coverage

1

Media coverage

  • TitleAdherence to Ombitasvir/Paritaprevir/r, Dasabuvir, and Ribavirin is >98% in the SAPPHIRE-I and SAPPHIRE-II Trials
    Media name/outletNational AIDS Treatment Advocacy Project
    CountryUnited States
    Date5/19/15
    PersonsFred Poordad